$2.75
1.79% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US74365N1037
Symbol
PTIX

Protagenic Therapeutics Inc Stock price

$2.75
-0.82 22.97% 1M
-1.00 26.60% 6M
-4.11 59.91% YTD
-7.89 74.15% 1Y
-30.97 91.85% 3Y
-62.77 95.80% 5Y
-1,729.22 99.84% 10Y
-363,713,277.25 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.05 1.79%
ISIN
US74365N1037
Symbol
PTIX
Industry

Key metrics

Basic
Market capitalization
$2.4m
Enterprise Value
$1.6m
Net debt
positive
Cash
$870.0k
Shares outstanding
540.0k
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
51.8%
Return on Equity
-545.3%
ROCE
5,922.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-5.3m | -
EBIT
$-5.3m | -
Net Income
$-5.2m | -
Free Cash Flow
$-3.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
3.6% | -
EBIT
3.5% | -
Net Income
12.8% | -
Free Cash Flow
27.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-10.0
FCF per Share
$-6.7
Short interest
1.2%
Employees
2
Rev per Employee
$0.0
Show more

Is Protagenic Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Protagenic Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Protagenic Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Protagenic Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Protagenic Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.05 2.05
86% 86%
-
- Research and Development Expense 3.36 3.36
24% 24%
-
-5.28 -5.28
4% 4%
-
- Depreciation and Amortization 0.05 0.05
25% 25%
-
EBIT (Operating Income) EBIT -5.33 -5.33
3% 3%
-
Net Profit -5.24 -5.24
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protagenic Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagenic Therapeutics Inc Stock News

Neutral
MCAP MediaWire
14 days ago
NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.
Neutral
GlobeNewsWire
14 days ago
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.
Neutral
Accesswire
3 months ago
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
More Protagenic Therapeutics Inc News

Company Profile

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Head office United States
Employees 2
Founded 1994
Website protagenic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today